Table 1.
Active Clinical Trials Targeting B7-H3 in Patients with Brain Tumors.
| Trial Number | Intervention | Phase | Launch Time | Settings | Sample Size | Patients | Pathology | Primary Endpoints |
|---|---|---|---|---|---|---|---|---|
| NCT04185038 | CAR-T therapy | I | 2019 | Seattle Children's Hospital, US | 90 | Children and young adults | DIPGs and refractory or recurrent CNS tumors | Safety and feasibility |
| NCT05474378 | CAR-T therapy | I | 2022 | Stanford University, US | 39 | Adults | Recurrent GBMs | Number of successful manufacturing products meeting the minimum dose range, the maximum tolerated dose, and the recommended phase II dose |
| NCT05366179 | CAR-T therapy | I | 2022 | University of North Carolina, US | 36 | Adults | Relapsed or refractory GBMs | Safety and tolerability, cytokine release syndrome, and neurotoxicity |
| NCT05241392 | CAR-T therapy | I | 2022 | Beijing Tiantan Hospital, China | 30 | Adults | Recurrent GBMs | Dose limiting toxicity and adverse events |
| NCT04385173 | CAR-T therapy | I | 2020 | Zhejiang University, China | 12 | Adults | Recurrent or refractory GBMs | Adverse events, maximum tolerated dose, overall survival, and progression-free survival |
| NCT04077866 | CAR-T therapy | I/II | 2019 | Zhejiang University, China | 40 | Adults | Recurrent or refractory GBMs | Overall survival |
| NCT04637503 | CAR-T therapy | I/II | 2020 | Shenzhen Geno-Immune Medical Institute, China | 100 | Adults | Relapsed and refractory neuroblastoma | Adverse events |
| NCT05063357 | ADC therapy | I | 2021 | Y-mAbs Therapeutics, US | 36 | Children and young adults | DIPGs that have not progressed following external beam radiation therapy. | Adverse events |
| NCT04743661 | ADC therapy | II | 2021 | Memorial Sloan Kettering Cancer Center and Y-mAbs Therapeutics, US | 62 | Children and young adults | Recurrent medulloblastoma and ependymomas | 2-year event free survival, and percentage of patients who met feasibility criteria in the ependymoma cohort |
| NCT05064306 | ADC therapy | I | 2021 | Memorial Sloan Kettering Cancer Center and Y-mAbs Therapeutics, US | NA | Children and young adults | CNS/leptomeningeal neoplasms | NA |
| NCT03275402 | ADC therapy | II/III | 2017 | Y-mAbs Therapeutics, US | 52 | Children | Neuroblastomas and CNS/leptomeningeal metastases | Overall survival rate at 3 years |
| NCT00089245 | ADC therapy | I | 2004 | Y-mAbs Therapeutics, US | 120 | Children and adults | Refractory, recurrent, or advanced CNS/leptomeningeal cancers | Treatment related toxicities |